Pepscan Therapeutics - Therapeutic peptides

Home > Home > Therapeutic peptides

News

27-03-2012: PerkinElmer announces collaboration with Pepscan Therapeutics for high throughput synthesis and screening of peptide libraries for drug discovery research

08-02-2012: Pepscan Therapeutics achieves milestones in research collaboration with Janssen R&D Ireland

06-12-2011: Pepscan Therapeutics presents protein mimicry platform for the discovery of anti-GPCR antibodies at International Antibody Conference

10-05-2011: Phylogica and Pepscan enter collaboration to optimise therapeutic phylomer drug candidates

04-04-2011: Pepscan appoints new Chief Business Officer

22-03-2011: Zealand Pharma and Pepscan awarded EU grant of EUR 0.9 million for the joint development of novel peptide drugs

10-03-2011: Pepscan Therapeutics closes a Research and License Agreement aimed at the development of novel vaccines.

03-01-2011: Mercator Therapeutics and Pepscan Therapeutics establish Research and Licensing Collaboration

28-09-2010: Pepscan Therapeutics announces establishment of Scientific Advisory Board

14-09-2010: Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals

01-09-2010: Oprichter Pepscan gehuldigd bij afscheid

28-04-2010: Pepscan signs partnering agreement with Immunovo for its therapeutic vaccin portfolio

Therapeutic peptides

CLIPS technology has shown to improve the activity and stability of peptides, and thus provides great opportunities for new therapeutic peptide drugs.

Home